NSRX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Nasus Pharma enrolls and doses the first patient in a Phase 1 study of NS003, an intranasal ondansetron formulationSep 29, 2026
- FDA cleared Nasus Pharma to initiate a clinical study of NS002 for anaphylaxisSep 14, 2026
- Nasus Pharma advanced NS002 toward a pivotal trial after positive Phase 2 results and reported annual updatesMar 25, 2026
- Nasus Pharma reported Phase 2 results showing NS002 delivered epinephrine faster and more effectively than EpiPenMar 16, 2026
- Nasus Pharma announced positive interim Phase 2 results for NS002 intranasal epinephrineJan 20, 2026